Revolution Medicines, Inc. Other Nonoperating Income (Expense)
Revolution Medicines, Inc. (RVMD) reported Other Nonoperating Income (Expense) of -$6.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-05
- Revolution Medicines, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was -$6.00K.
- Revolution Medicines, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was $117.00K.
- Revolution Medicines, Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Revolution Medicines, Inc. other nonoperating income (expense) for the quarter ending 2025-06-30 was -$32.00K, a 300.00% decline year-over-year.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month |
|---|---|---|---|
| 2026-06-30 | -$6.00K 10-Q · filed 2026-08-05 | -$123.00K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $117.00K 10-Q · filed 2026-05-06 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | -$32.00K derived: sum of 2 quarters · filed 2026-08-05 | -$42.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$32.00K 10-Q · filed 2026-08-05 | -$42.00K 10-Q · filed 2026-08-05 | |
| 2025-03-31 | -$10.00K 10-Q · filed 2026-05-06 | ||
| 2024-09-30 | $282.00K 10-Q · filed 2025-11-05 | $298.00K derived: sum of 2 quarters · filed 2025-11-05 | -$2.51M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $16.00K 10-Q · filed 2024-08-07 | -$2.79M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | -$2.81M 10-Q · filed 2025-05-07 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |